B+
Bull case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NXTC
NextCureDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
-0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+38.4
Score
AI commentary
The Q2 update is mixed: the Avere merger, proposed $320 million financing, and LigaChem continuation add strategic optionality, while declining cash, restructuring, clinical transition, and weak peer comparability constrain forward visibility. Analyst revisions, earnings-surprise consensus, target changes, and post-print price reaction are unavailable. Insider buying is supportive secondary sentiment evidence only and does not establish operating improvement. [#SEC-8K-2026-08-06] [#SEC-FORM4-2026-08-03]
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-31catalystQ2 cash decline and restructuring pressureHigh impact
Cash, cash equivalents, and marketable securities fell to $20.1 million at June 30, 2026 from $41.8 million at year-end; restructuring also produced $5.1 million of asset-impairment costs. [#SEC-8K-2026-08-06]
2026-12-31eventLigaChem continuation and LNCB74 progress updateHigh impact
LigaChem elected to continue LNCB74 development as sole developing party, while NextCure remains eligible for potential milestone and royalty payments. A second-half 2026 trial progress update had previously been planned; efficacy, safety, enrollment, timing, and economics remain uncertain. [#SEC-8K-2026-08-06] [#SEC-8K-2026-05-07]
2026-12-31catalystAvere financing and merger closingHigh impact
Avere's concurrent private financing is expected to generate approximately $320 million in gross proceeds immediately before the proposed all-stock merger, which is targeted for the second half of 2026 and remains subject to customary closing conditions. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology